NDAORALTABLET, EXTENDED RELEASE
Approved
Apr 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
KLOR-CON (potassium chloride) by Ascentage Pharma is tissues. First approved in 1986.
Drug data last refreshed 5h ago · AI intelligence enriched 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KLOR-CON is an oral extended-release tablet formulation of potassium chloride, a small-molecule electrolyte replacement therapy. It restores and maintains normal serum potassium levels essential for nerve impulse transmission, muscle contraction, and cardiac function. Potassium ions are critical for intracellular tonicity and normal renal function.
$11.0MPart D
LOE ApproachingStable
Mature, stable product approaching loss of exclusivity with modest commercial footprint; limited team expansion expected.
Mechanism of Action
tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KLOR-CON offers limited career growth opportunity given its mature lifecycle, commodity market positioning, and approaching loss of exclusivity. Roles available are primarily commercial and sales-focused with minimal exposure to innovation, clinical development, or strategic differentiation.
Brand Manager
Worked on KLOR-CON at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.